COVID-19 drug trial halted: ABX464 fails to show benefit in High-Risk patients
Disease control
Terminated
This study tested an experimental drug called ABX464 in 509 adults aged 65 or older, or aged 18+ with risk factors like obesity or diabetes, who had COVID-19. The goal was to see if the drug could reduce inflammation and prevent severe breathing failure. However, the study was st…
Phase: PHASE2, PHASE3 • Sponsor: Abivax S.A. • Aim: Disease control
Last updated May 04, 2026 16:23 UTC